---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010987"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:56:03.952150+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aclaris CSO Joseph Monahan shifts to part-time; base salary reduced to $280,800

## Summary
- Monahan will serve as Chief Scientific Officer at 60% of full-time schedule as of July 1, 2023.
- Annual base salary reduced to $280,800; annual bonus eligibility pro-rated for part-time service.
- Amended employment agreement has initial two-year term with automatic one-year renewals unless 90-day notice given.
- Monahan remains in role; prior agreement superseded.

## SEC filing metadata
- accession: 0001558370-23-010987
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/0001558370-23-010987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/acrs-20230609x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010987
- JSON: https://secwatch.observer/filing/0001558370-23-010987.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010987.txt

## Key facts
- Executive change
  Joseph Monahan changed role as Chief Scientific Officer at Aclaris Therapeutics, Inc..
  - Action: Shift to part-time status
  - Role: Chief Scientific Officer
  source text: Dr. Monahan will continue to serve as the Company’s Chief Scientific Officer but will shift to part-time status, pursuant to which he will provide services at 60% of a full-time schedule.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/0001558370-23-010987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.